---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-458624"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2026-11-12T21:41:11+00:00"
generated_at: "2026-11-12T21:42:05.098904+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution

## Summary
- Avenzo Therapeutics merger under May 31, 2026 agreement expected to close after market close Nov 20, 2026; Nasdaq approved listing of common stock for the deal.
- Special cash distribution of $13.90/share to holders of record Nov 5, 2026; deposit with transfer agent Nov 19, payments expected to begin Nov 30, 2026.
- Nasdaq due-bill period runs from Nov 5 record date through close on Nov 20; buyers in that period receive the cash distribution, while sellers do not.
- Reverse stock split expected effective 4:01 p.m. ET on Nov 20, 2026; timing and amount of the cash distribution are unaffected.
- Contingent value rights expected distributed Nov 23, 2026 to common holders, pre-funded warrants, RSUs and In the Money Parent Options as of Nov 5.

## SEC filing metadata
- accession: 0001193125-26-458624
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2026-11-12T21:41:11+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000119312526458624/0001193125-26-458624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000119312526458624/d176721d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-458624
- JSON: https://secwatch.observer/filing/0001193125-26-458624.json
- Plain text: https://secwatch.observer/filing/0001193125-26-458624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.